Cubist Pharmaceuticals, Inc. (CBST) reported a third-quarter net income of 65 cents per share, which was much higher than the Zacks Consensus Estimate of 33 cents. The company’s net income was 48 cents per share in the year-ago quarter. The higher profit in the quarter was primarily because of increased sales coming from all the segments. Revenues in the quarter increased 28% to $143.5 million. U.S. product revenues increased 26.1% to $137.66 million in the quarter. Cubist recorded international product revenues of $3.93 million as against $1.43 million last year. Service revenues came in at $1.50 million from $1.42 million, and other revenues increased to $0.45 million from $0.39 million. Research & Development (R&D) spend for the quarter increased 24.1% to $35.5 million. Sales & Marketing expenses for the quarter decreased 15% to $18.9 million. General & Administrative (G&A) spend increased to $12.8 million from $9.3 ...

It was a Wednesday afternoon when Cubist Pharmaceuticals have publicly announced that they have been named to be in the top spot in the MassEcon Sixth Annual Team Massachusetts Economic Impact Awards in the Greater Boston Region. The Massachusetts Alliance for Economic Development also known as MassEcon is a private, non-profit partnership of business, industry leaders and government who are working hard for the economic growth of Massachusetts. With two other pharmaceutical companies bagging the silver and bronze level, it was the life science companies that sweep the awards in the Greater Boston Region.

Cubist Pharmaceuticals Inc. is a biopharmaceutical company that is into the research and development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

The winning companies were judged on their investment in

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Thursday August 13, 2009

PennyOmega.com Stock Report!

**************************************************************

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it is teaming up with the New England Patriots Radio Network, WBZ FM 98.5 The Sports Hub, and its 36-station radio network throughout New England, during the 2009 New England Patriots season to recognize innovative science teachers in middle schools and high schools throughout New England.

Kendall Law Group, led by a former federal judge and former US Attorney, today announced that a lawsuit has been filed against Varian, Inc. (NASDAQ: VARI) challenging the proposed acquisition of Varian by Agilent Technologies (NYSE: A). If you wish to learn more about your rights

...

DrStockPick.com Stock Report!

Tuesday August 4, 2009

**************************************************************

Hill International (NYSE:HIL), the global leader in managing construction risk, announced today that it has received a contract from the U.S. General Services Administration to provide construction management services during the modernization of the Thomas S. Foley U.S. Courthouse in Spokane, Washington. The five-year contract has an estimated value to Hill of approximately $2.0 million.

The Macerich Company (NYSE: MAC) today announced results of operations for the quarter ended June 30, 2009 which included total funds from operations (”FFO”) diluted of $59.9 million or $.67 per diluted share compared to $1.12 per diluted share for the quarter ended June 30, 2008. For the six months

...

Highlights include Theravance, Inc. (THRX), ViroPharma, Inc. (VPHM), Cubist Pharmaceuticals, Inc. (CBST), Pfizer, Inc. (PFE), Wyeth (WYE) and Johnson & Johnson (JNJ).Theravance Neports Narrower Loss, Awaits 2 FDA ApprovalsNarrower 1Q09 net loss, improvement anticipated in the coming quarters        Theravance, Inc. (THRX) reported 1Q09 results on April 22, 2009.Revenue increased 70% to $9.5 million for the quarter compared to $5.6 million in the same period last year. The increase was primarily due to the recognition of the remaining deferred revenue of the LAMA program since the program has been returned to the company from GlaxoSmithKline plc (GSK). In our model we had projected higher revenue with the expectation of FDA approval of Telavancin, which now seems to be possible during 2Q or 3Q 2009. Net loss for the first quarter was at ...

Highlighted stocks include Alnylam Pharmaceuticals Inc. (ALNY), Merck & Co., Inc. (MRK), Roche Holding Ltd. (RHHBY), Novartis (NVS) and Biogen Idec (BIIB).Fourth Quarter Financial Results Fall Short of Our Expectations Alnylam relies on research collaborations, grants, and licensing of the RNAi technology outside its core focus area for its major revenue sources.The company reported 4th quarter of 2008 finanical results on February 24, 2009. Revenues in the quarter were $24.4 million, compared to $18.2 million for the same period last year. Revenues for the 4th quarter of 2008 included $14.0 million of net collaboration revenues related to the company's alliance with Roche (RHHBY), as well as $5.4 million of revenues from the company's alliance with Takeda Pharmaceuticals Company Limited.Revenues from the 4th quarter also included $5.0 million of expense reimbursement and amortization revenues from Novartis ...